Altre lingue Innoviva, Inc.

Azioni

INVA

US45781M1018

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 18/06/2024			Variaz. 5gg	Var. 1 gen.
16,22 ^USD	+0,37%		+2,01%	+1,12%

18/06	INNOVIVA, INC. : prospettiva positiva di Cantor Fitzgerald	ZM
10/06	Transcript : Innoviva, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	03/06
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	21/05
Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China	20/05
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20/05
Innoviva: Q1 Earnings Snapshot	08/05
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M	08/05
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	08/05
Innoviva, Inc. Appoints Derek Small to the Board of Directors	08/05
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress	08/05
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Innoviva to Participate in the BofA Securities Health Care Conference	08/05
Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	25/04
Innoviva, Inc.'s Equity Buyback announced on November 9, 2022, has closed with 7,807,887 shares, representing 11.78% for $100 million.	25/04
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24/04
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24/04
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	29/02
Innoviva: Q4 Earnings Snapshot	29/02
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	29/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Innoviva, Inc.

Azioni

INVA

US45781M1018

Altre lingue

Filtri